RMDA – Golden Zone Consolidation & Pricing Power
RMDA – Golden Zone Consolidation & Pricing Power 📉💊
The Reality: A true fundamental "Engine" disguised by debt! ⚙️
RMDA's revenue growth is massive (+48%), and the core business is far more profitable than the bottom line looks.
While net income is EGP 268M, the operating income is nearly EGP 942M.
The "gap" is simply the cost of debt used to fuel their high-margin expansion into chronic-care medicine. 🏥💎
The Cash Power: RMDA is a cash-flow monster, generating EGP 1.22B from operations annually. 💰
Physical cash conversion is high, and the company has successfully pushed through price increases across its portfolio a move that will fully impact the 2026 bottom line.
Despite EGP 3.1B in liabilities, the growth in cash flow is keeping the debt manageable. 🛡️⚡
Technical Analysis:
The "Correction" is meeting the "Golden Ratio." 🎢🧗
The Golden Zone: The stock has corrected 50% of its previous wave and is now finding support in the "Golden Zone" (61.8% Fib) of the last dip.
The RSI Warning: We have a bearish RSI divergence from the last high.
This means while the price is stabilizing, the momentum isn't "explosive" yet.
Expect more consolidation before a breakout. 📉🩹
The Trigger: The immediate hurdle is 4.73.
A daily close above this level invalidates the bearish divergence and opens the door for a retest of the 5.12 ATH. 🚀🗝️
The Safety Net: If the current level fails, the next major support is at 4.40.
For conservative investors, this is the "Add" zone to increase your share count. ⚓🧱
Sharia Status: ✅ Confirmed Compliant. Rameda is a high-liquidity member of the EGX33 Shariah Index (April 2026).
Its balance sheet and core pharmaceutical activities pass all quantitative screens. ☪️📜
Verdict: RMDA is a "High-Quality Buy" on dips. 🏗️🏎️
The fundamental strength of the core business provides a massive safety margin even if technical momentum is currently lagging.
Watch for the 4.73 break to signal the start of the run toward 5.35. 🛡️🔝
If you like my posts, please follow and boost 🙌
🎁 Get a $15 discount on your next subscription:
🔗 tradingview.com/pricing/?share_your_love=mnmabroukw36ix ✨💸
The Reality: A true fundamental "Engine" disguised by debt! ⚙️
RMDA's revenue growth is massive (+48%), and the core business is far more profitable than the bottom line looks.
While net income is EGP 268M, the operating income is nearly EGP 942M.
The "gap" is simply the cost of debt used to fuel their high-margin expansion into chronic-care medicine. 🏥💎
The Cash Power: RMDA is a cash-flow monster, generating EGP 1.22B from operations annually. 💰
Physical cash conversion is high, and the company has successfully pushed through price increases across its portfolio a move that will fully impact the 2026 bottom line.
Despite EGP 3.1B in liabilities, the growth in cash flow is keeping the debt manageable. 🛡️⚡
Technical Analysis:
The "Correction" is meeting the "Golden Ratio." 🎢🧗
The Golden Zone: The stock has corrected 50% of its previous wave and is now finding support in the "Golden Zone" (61.8% Fib) of the last dip.
The RSI Warning: We have a bearish RSI divergence from the last high.
This means while the price is stabilizing, the momentum isn't "explosive" yet.
Expect more consolidation before a breakout. 📉🩹
The Trigger: The immediate hurdle is 4.73.
A daily close above this level invalidates the bearish divergence and opens the door for a retest of the 5.12 ATH. 🚀🗝️
The Safety Net: If the current level fails, the next major support is at 4.40.
For conservative investors, this is the "Add" zone to increase your share count. ⚓🧱
Sharia Status: ✅ Confirmed Compliant. Rameda is a high-liquidity member of the EGX33 Shariah Index (April 2026).
Its balance sheet and core pharmaceutical activities pass all quantitative screens. ☪️📜
Verdict: RMDA is a "High-Quality Buy" on dips. 🏗️🏎️
The fundamental strength of the core business provides a massive safety margin even if technical momentum is currently lagging.
Watch for the 4.73 break to signal the start of the run toward 5.35. 🛡️🔝
If you like my posts, please follow and boost 🙌
🎁 Get a $15 discount on your next subscription:
🔗 tradingview.com/pricing/?share_your_love=mnmabroukw36ix ✨💸
Publications connexes
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Publications connexes
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.